The Scottish Normal Pressure Glaucoma Study
Research type
Research Study
Full title
The Scottish Glaucoma Biobank
IRAS ID
215164
Contact name
Andrew Tatham
Contact email
Sponsor organisation
NHS Lothian Research and Development
Duration of Study in the UK
2 years, 11 months, 30 days
Research summary
Glaucoma, the most common cause of irreversible blindness, is a disease of the optic nerve that leads to gradual loss of vision. The aim of this study is to develop a Scottish Glaucoma Biobank to study mechanisms of disease in glaucoma. We hope to identify clinical and genetic factors associated with higher risk of visual loss. The study will enable us to examine whether a new series of tests, which are already available but not in routine use, add value to predicting whether someone with glaucoma is at risk of losing vision quickly. If we are able to identify novel risk factors for worsening of glaucoma, we may be able to identify potential targets for new treatments. Identification of new risk factors for disease progression would also enable better risk profiling of patients, helping to determine those who need closer follow up or more aggressive treatment. The study will be conducted at two sites, Princess Alexandra Eye Pavilion Edinburgh and Queen Margaret's Hospital Fife, and include 100 subjects with glaucoma and 50 control subjects.
REC name
South East Scotland REC 01
REC reference
17/SS/0008
Date of REC Opinion
23 Feb 2017
REC opinion
Further Information Favourable Opinion